zulu9812 said:
from The Guardian
This is simply appalling. This is why healthcare should have no place for goddamned market forces.
I always note your posts with suspicion because they often turn out to be wrong somehow. With this in mind, I investigated this article in The Guardian.
As I suspected, the article is misleading on several counts.
First, it presents old news as new news. This is actually common in the news media when it reports medical news. This article was first published on Oct 17, 2005 on
WebMD. Interestingly, The Guardian reported the exact same scenario on June 17, 2006 as had been reported in Oct 17, 2005, even though you would think something had changed by now. This leads me to suspect it's a regurgitation, with no effort at investigating the facts. (I just noticed that it's even at the same day of the month, which makes it even more suspicious.)
Second, the article suggests that Lucentis and Avastin are largely the same drug, when in fact they're not. It also implies that the drug company alone, Genentech, is responsible for attempting to withold the drug for ophthalmologic use when in fact, their concern of its safety is repeated by many ophthalmologic authorities, none of which are connected to pharmaceutical corporations.
Third, the article suggests that Genentech's request to avoid the use of Avastin for use in macular degeneration should be heeded. Doctors are not bound by a drug company's request to do anything. They are free to use any drug in any way they see appropriate, including "off label" use, which is what has been done with Avastin this whole time. As long as the drug is approved for use by the FDA for anything, and the doctor can justify its role by reasoning, it can be used. I'm pretty sure it works the same way in England. So whether Genentech gets anything it wants or not, it doesn't matter! Ophthalmologists will still use what they want. What's more is that there's nothing stopping anyone from launching a randomized double-blinded (no pun intended) clinical trial to compare Avastin to other treatments, even if they aren't the owners of any of the treatments. This happens all the time. It's a myth that only drug companies can undertake clinical trials. The only thing that the drug companies are able to afford that others may not is the research to come up with the drug in the first place, but not just to test it.
Fourth, the article complete ignores the fact that there are other, similar drugs, available for use.